A team at the Peter Mac is planning for first-in-human trials in five years, hoping this new therapy will eschew the ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Cis-regulatory elements (CREs)—including promoters, enhancers, silencers, and insulators—are critical non-coding DNA ...

The FDA’s Orphan Drug Designation offers incentives like seven years of U.S. market exclusivity, tax credits for clinical ...

Our cells' identity is shaped by DNA tags called methylation. New tech, scDEEP-mC, maps these tags in single cells with ...